Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX   US5288721047

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/23/2015 03/24/2015 03/25/2015 03/26/2015 03/27/2015 Date
1.06(c) 1.03(c) 0.9687(c) 0.952(c) 0.9505(c) Last
2 837 754 1 371 530 7 065 086 1 821 351 1 725 975 Volume
-3.64% -2.83% -5.95% -1.72% -0.16% Change
More quotes
Financials ($)
Sales 2015 4,78 M
EBIT 2015 -133 M
Net income 2015 -136 M
Debt 2015 -
Yield 2015 -
Sales 2016 28,2 M
EBIT 2016 -144 M
Net income 2016 -152 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 144x
Capi. / Sales 2016 24,4x
Capitalization 689 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. engages in discovery and development of breakthrough treatments for human disease.The company primarily focuses on the discovery of the functions and pharmaceutical utility of genes and the use of those gene function discoveries in the discovery and development of... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
03/25 LEXICON PHARMACEUTICALS : and Ipsen Expand Their Licensing and Commercialization..
03/25 LEXICON PHARMACEUTICALS : Announces First Patient Screened in Pivotal Phase 3 Cl..
03/18 IPSEN : Lexicon and Ipsen Expand Their Licensing and Commercialization Agreement..
03/16 LEXICON PHARMACEUTICALS : Completes Enrollment in Pivotal Phase 3 Clinical Trial..
03/12 LEXICON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
03/11 LEXICON PHARMACEUTICALS : To Report Fourth Quarter And Year End 2014 Financial R..
03/09 LEXICON PHARMACEUTICALS : Completes Enrollment In Pivotal Phase 3 Clinical Trial..
03/05 LEXICON PHARMACEUTICALS : LXRX) is Trading Higher on Unusual Volume for March 05
More news
Sector news : Bio Therapeutic Drugs
03/27 ISIS PHARMACEUTICALS : Earnings Coverage - Isis Pharma
03/26 Alliance invokes Elliott track record in appeal against board shake-up
03/26 ACTELION : receives marketing approval for Opsumit (macitentan) in pulmonary art..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/20 Lexicon Pharmaceuticals - A Diamond In The Rough?
03/06 Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q4 2014 Results - Earning..
03/04 Lexicon Pharma Q4 and FY14 results
03/04 Lexicon Pharmaceuticals beats by $0.03, beats on revenue
03/03 Notable earnings before Wednesday's open


Comments 
Advertisement
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF